Abstracts Archive - Page 790 of 2425 - ACR Meeting Abstracts

Abstract Number: 2030 • ACR Convergence 2020
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort
Denis Poddubnyy¹, Valeria Rios Rodriguez², Murat Torgutalp², Ani Dilbaryan², Maryna Verba², Mikhail Protopopov², Fabian Proft², Judith Rademacher², Hildrun Haibel², Martin Rudwaleit³ and Joachim Sieper², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: There are conflicting data on the effect of non-steroidal anti-inflammatory drugs (NSAIDs) on radiographic spinal progression in axial spondyloarthritis (axSpA). One randomized controlled trial…
Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Augusta Ortolan¹, Victoria Navarro-Compán², Alexandre Sepriano³, Robert Landewé⁴, Désirée van der Heijde⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center, Padova, Italy, ²Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ³Leiden University Medical Center, Portela Loures, Portugal, ⁴Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
Abstract Number: 2032 • ACR Convergence 2020
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis
Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Burkhard Muche¹, Anne-Katrin Weber¹, Susanne Lüders¹, Hildrun Haibel¹, Maryna Verba¹, Joachim Sieper¹ and Denis Poddubnyy², ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is few data available regarding differences in body composition and its possible changes in patients with ankylosing spondylitis (AS) treated with biological disease-modifying…
Abstract Number: 2033 • ACR Convergence 2020
Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Brian Skaug¹, Marka Lyons¹, William Swindell², Gloria Salazar¹, Julio Charles¹, Connor Vershel¹, Maureen Mayes³ and Shervin Assassi³, ¹University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²The Jewish Hospital, Department of Internal Medicine, Cincinnati, OH, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Numerous studies have revealed dysregulated gene expression in the skin of systemic sclerosis (SSc) patients, with varying degrees of inflammatory/immune and fibroblast upregulation. However,…
Abstract Number: 2034 • ACR Convergence 2020
Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
Janine Schniering¹, Malgorzata Maciukiewicz¹, Hubert Gabrys², Matthias Brunner¹, Christian Blütghen³, Chantal Meier¹, Sophie Braga-Lagache⁴, Anne-Christine Ulgry⁴, Manfred Heller⁴, Oliver Distler¹, Matthias Guckenberger², Havard Fretheim⁵, Anna-Maria Hoffmann-Vold⁵, Christos Nakas⁶, Thomas Frauenfelder³, Stephanie Tanadini-Lang² and Britta Maurer⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Radiation Oncology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁴Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Switzerland, Bern, Switzerland, ⁵Department of Rheumatology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Norway, Oslo, Norway, ⁶Laboratory of Biometry, University of Thessaly, Volos, Greece, Volos, Greece, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich
Background/Purpose: Radiomics describes the in-depth analysis of tissue phenotypes by computational retrieval of high-dimensional quantitative imaging features including tissue intensity, texture, and wavelet characteristics. Here,…
Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…
Abstract Number: 2036 • ACR Convergence 2020
Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
Ariane Barbacki¹, Murray Baron², Mianbo Wang³, Yuqing Zhang⁴, Mandana Nikpour⁵ and Ada Man⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, ⁵The University of Melbourne at St. Vincent's Hospital, Melbourne, Victoria, Australia, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Systemic sclerosis (SSc) is a rare systemic autoimmune disease associated with a high mortality and characterized by the accrual of organ damage over time.…
Abstract Number: 2037 • ACR Convergence 2020
Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Anastasiya Muntyanu¹, Bina Kassamali², Ruth Ann Vleugels³ and Avery LaChance³, ¹McGill University, Montreal, QC, Canada, ²Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune sclerosing disease with a 10-year survival rate of less than 65%. This rate has remained unchanged for…
Abstract Number: 2038 • ACR Convergence 2020
Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
Jane Zhu¹, Smriti Prasad², Kaila Schollaert-Fitch³, Robert Haley⁴, Kathryn Torok³ and Heidi Jacobe², ¹UT Southwestern Medical Center, Dallas, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Texas Southwestern Medical Center, Dallas
Background/Purpose: Morphea, or localized scleroderma, is an inflammatory condition of the skin and soft tissue that results in excessive collagen deposition, often producing permanent functional…
Abstract Number: 2039 • ACR Convergence 2020
Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma
Britany Adler¹, Ami Shah², Francesco Boin³, Paul Wolters³, Livia Casciola-Rosen⁴ and Antony Rosen¹, ¹Johns Hopkins University, baltimore, MD, ²Johns Hopkins University School of Medicine, Ellicott City, MD, ³University of California, San Francisco, San Francisco, CA, ⁴Johns Hopkins University, Johns Hopkins University, MD
Background/Purpose: Scleroderma is a systemic fibrosing disease of unknown etiology that often manifests with interstitial lung disease (ILD). Prior studies have found an association between…
Abstract Number: 2040 • ACR Convergence 2020
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Martina Gahlemann⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Susanne Stowasser⁶ and Kristin Highland⁸, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Netherlands, ³Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁴University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁵Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 2041 • ACR Convergence 2020
Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts
Kristofer Andréasson¹, Sungeun Lee², Venu Lagishetty², Meifang Wu², Natalie Howlett², James English², Roger Hesselstrand¹, Jonathan Jacobs² and Elizabeth Volkmann³, ¹Lund University, Lund, Sweden, ²University of California, Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Previous studies have demonstrated alterations in GI microbiota of patients with systemic sclerosis (SSc) compared with healthy controls [1]. However, these prior studies did…
Abstract Number: 2042 • ACR Convergence 2020
A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis
Natalie Howlett¹, Sungeun Lee¹, Venu Lagishetty¹, Zsuzsanna McMahan², Meifang Wu¹, Jonathan Jacobs¹ and Elizabeth Volkmann³, ¹University of California, Los Angeles, Los Angeles, ²Johns Hopkins University, Baltimore, ³University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Dietary restriction of short-chain fermentable oligosaccharides, disaccharides, monosaccharides and polyols (low FODMAP) has been found to reduce GI symptoms in patients with IBS and…
Abstract Number: 2043 • ACR Convergence 2020
Identification and Validation of Citrulline Specific TCRs in CD4+T Cells in Rheumatoid Arthritis
Ravi Kumar¹, Niyaz Yoosuf², Sanjay Boddul², Christina Gerstner³, Sara Turcinov⁴, Anatoly Dubnovitsky⁵, Fredrik Wermeling², Karine Chemin⁶ and Vivianne Malmström⁷, ¹Division of Rheumatology, Department of Medicine, Stickholm, Stockholms Lan, Sweden, ²Division of Rheumatology, Department of Medicine, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, ⁶Division of Rheumatology, Department of Medicine, Stockholm, Stockholms Lan, Sweden, ⁷Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Citrulline (cit) autoimmunity is central in rheumatoid arthritis (RA), including both anti-citrulline protein antibodies (ACPA) and autoreactive CD4+ T cells. While the ACPA are…
Abstract Number: 2044 • ACR Convergence 2020
Complex, Dynamic Attributes of Antigen-specific T Cells in Rheumatoid Arthritis
Eddie James¹, Virginia Muir², Cliff Rims¹, Hannes Uchtenhagen³, Anne Hocking³, Sylvia Posso³, Heather Bukiri⁴, Jeffrey Carlin⁴, Bernard Ng⁵, Peter Linsley³ and Jane Buckner¹, ¹Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Center for Systems Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA, ⁵VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: CD4+ T cells are implicated in the pathogenesis of rheumatoid arthritis (RA) due to strong genetic association with HLA class II alleles, the presence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].